Bull Case

Vyvgart and Vyvgart Hytrulo expand faster across generalized myasthenia gravis, CIDP, and new indications, lifting revenue growth above peers with narrower label concentration.

Successful label expansions and geographic penetration sustain premium pricing and mix, supporting operating leverage despite high launch spending versus larger rare-disease peers.

Commercial execution in autoimmune neurology improves physician adoption and patient persistence, allowing ARGX to outgrow comparable antibody platforms with slower multi-indication scaling.

Strong cash generation and net cash balance fund pipeline expansion without dilution, preserving strategic flexibility versus more levered biotech peers during development cycles.

Base Case

Vyvgart franchise growth remains the main driver, with continued uptake in approved autoimmune indications offsetting slower expansion than the bull case.

Operating margin stays solid as commercialization scales, but elevated R&D and launch investment keep profitability below mature specialty peers with broader portfolios.

Pipeline progress adds optionality, yet revenue concentration in a few products keeps forward outcomes more dependent on execution than diversified biopharma peers.

Net cash and high interest coverage reduce financing risk, allowing ARGX to sustain development spending better than peers that rely on external capital.

Bear Case

Vyvgart growth decelerates if competitive launches or slower reimbursement adoption limit share gains, leaving ARGX more exposed than diversified rare-disease peers.

Pipeline setbacks or delayed label expansion reduce the pace of new revenue streams, increasing dependence on the core franchise for longer than expected.

Higher-than-planned commercialization and trial costs compress margins, narrowing the gap versus peers with established scale and more efficient launch economics.

Even with a strong balance sheet, weaker operating momentum would pressure valuation support because current multiples already assume sustained above-peer growth.

Overall Score

ARGX’s forward profile remains strong because Vyvgart-led growth, cash-rich funding, and expanding autoimmune indications outweigh concentration risk and execution uncertainty versus peers.